Dr. Ankit N. Mehta, M.D.

Medicare patients and services

Medicare patients, 2024

123

Services billed

292

Patients’ average age

70

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 12 companies reported 176 payments worth $216,855 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Texas →

Industry-funded research

Named as a principal investigator on 12 industry-funded studies in 2025, from 9 companies. The companies reported $663,696 in research payments for these studies, mostly to the institutions running them.

• An Adaptive, Randomized, Double-blind, Dose Exploration, Parallel Group, Placebo Controlled, Multicenter Phase 2 Trial to Evaluate the Efficacy, Safety and Tolerability of LNP023 in Combination With Standard-of-care W…
  Novartis Pharmaceuticals Corporation
• A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Participants With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
  Amgen Inc.
• A Phase 2, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted NEXT CAR T Cells, in Participants with Active SLE (Including Lupus Nephritis) with Inadequate Response to Glucocorticoids and at Least 2…
  Celgene Corporation
• A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease
  Genzyme Corporation · Active, not recruiting · NCT05206773
• Fabry Disease Registry & Pregnancy Sub-registry
  Sanofi US Services Inc. · Recruiting · NCT00196742
• Open-Label Expanded Access Treatment With Pegunigalsidase Alfa for Fabry Disease Patients
  Chiesi USA, Inc. · Approved for marketing · NCT04552691
• A Multicenter, Randomized, Double-blind, Placebo-controlled, Four-arm, Parallel-group, Dose-finding Phase 2b Study to Investigate the Safety and Efficacy of TIN816 Via a Single Intravenous Infusion in the Treatment of…
  Novartis Pharmaceuticals Corporation
• A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease
  Genzyme Corporation · Active, not recruiting · NCT05280548
• A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
  Genzyme Corporation · Recruiting · NCT06500702
• A phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd …
  AstraZeneca Pharmaceuticals LP

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Nephrology (Kidney) clinicians in Dallas

• Dina Abdelwahab, MD
• Nashila Abdulrahim, DO
• Melby Abraham, M.D.
• Sailaja Adari, MD
• Monika Aggarwal, M.D.
• Irfan A. Agha, M.D.
• Sana M. Ahmed, MD
• Shahbaz Ahmed, MD